-
Venue: New Delhi, April 13-14, 2026.
-
Theme: “Discover in India: Leapfrogging Life-Sciences Innovation”.
-
Organisers: By the Department of Pharmaceuticals (DoP) in collaboration with the Federation of Indian Chambers of Commerce and Industry (FICCI) and the Indian Pharmaceutical Alliance (IPA).
Significance of the Indian Pharma Industry:
-
A key global player, ranking 3rd by volume and 14th by value.
-
Contributes approximately 1.7% to India's GDP.
-
Serves as a crucial platform for dialogue between the industry and the government.
-
Robust manufacturing capabilities: supplies nearly 20% of global generic medicines and meets about 70% of global vaccine demand.
- India has the highest number of US-FDA compliant Pharma plants outside of USA and its API industry is third largest in the world, with 57% of APIs on the WHO.
Key Government Initiatives & Commitments:
-
Advancing Innovation:
-
Biopharma Shakti Initiative: A ₹10,000 crore outlay to boost biopharmaceutical innovation capabilities.
-
PRIP Scheme: {Promotion of Research & Innovation in Pharma-MedTech Sector (PRIP) Scheme} aiming to deepen industry-academia collaboration and accelerate new therapy development.
-
Strengthening Manufacturing & Self-Reliance:
-
Priority on domestic manufacturing supported by schemes like the Production Linked Incentive (PLI) and the establishment of bulk drug parks to create resilient supply chains.
-
Affordable Healthcare:
-
Commitment to affordable healthcare through initiatives like the Pradhan Mantri Bharatiya Jan Aushadhi Pariyojana, which is expanding access to quality and cost-effective medicines nationwide.